Phillip Minar, MD, MS
- Medical Director, Shubert-Martin Inflammatory Bowel Disease Center
- Program Director, Advanced Pediatric IBD Fellowship Training
- Associate Professor, UC Department of Pediatrics
- phillip.minar@cchmc.org
- Board Certified
About
BA: Duquesne University, Pittsburgh, PA.
MS: Clinical and Translational Research, University of Cincinnati, Cincinnati, OH.
MD: Medical College of Wisconsin, Milwaukee, WI.
Residency: Pediatrics, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, WI.
Fellowship: Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's, Cincinnati, OH.
Certification: General Pediatrics; Pediatric Gastroenterology.
Interests
Pediatric inflammatory bowel disease; evidence-based care for children and young adults with IBD; sustained, prednisone-free clinical remission
Services and Specialties
Interests
Application of personalized medicine in the care of children and young adults with IBD through the discovery of surrogate biomarkers of intestinal inflammation; sensitive and specific pharmacodynamic biomarker, neutrophil CD64; innovative pharmacokinetic dosing platform, RoadMAB; personalized dosing of biologic therapies for patients with IBD; novel method to dose infliximab (guided by RoadMAB) from the start of treatment and throughout the maintenance phase to assess both the effectiveness and safety of model-informed precision dosing.
Research Areas
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Machine Learning Modeling for Predicting Infliximab Pharmacokinetics in Pediatric and Young Adult Patients With Crohn Disease: Leveraging Ensemble Modeling With Synthetic and Real-World Data. Therapeutic Drug Monitoring. 2026; 48(1):98-104.
Model-Informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's Disease. Clinical Pharmacology and Therapeutics. 2026; 119(2):555-563.
Comment on a Risk Stratification Tool for Relapse After Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases. American Journal of Gastroenterology. 2026; 121(1):101-102.
CAPTURE IBD: Advancing Precision Medicine in Pediatric IBD. Inflammatory Bowel Diseases. 2026; 32(1):188-190.
Markers of Gut Inflammation in Pediatric Acute Pancreatitis. Pancreas. 2025.
Hybrid Population Pharmacokinetic-Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn's Disease. Clinical Pharmacokinetics. 2025; 64(11):1669-1679.
Magnetic resonance imaging for suspected perianal Crohn's disease in children: a multi-reader agreement study. European Radiology. 2025; 35(9):5856-5863.
Acute pancreatitis gut dysbiosis persists at 1-year follow-up and is associated with clinical outcomes. Journal of Pediatric Gastroenterology and Nutrition. 2025; 81(3):690-698.
Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease. Inflammatory Bowel Diseases. 2025; 31(7):1841-1850.
Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease: A Nationwide Survey of Anti-TNF Therapy Practices, Attitudes, and Barriers. Crohn's & Colitis 360. 2025; 7(3):otaf050.
From the Blog
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey